subscribeSubscribe
The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS

The CHMP has Adopted a Negative Opinion for Omburtamab for the Treatment of CNS
GLOBENEWSWIRE
16 Dec 2022
Share Share
U.S. FDA declines to approve Y-mAbs`s pediatric cancer drug

U.S. FDA declines to approve Y-mAbs`s pediatric cancer drug
HEALTH ET
02 Dec 2022
Share Share
Y-mAbs Announces Complete Response Letter for Omburtamab BLA

Y-mAbs Announces Complete Response Letter for Omburtamab BLA
GLOBENEWSWIRE
01 Dec 2022
Share Share
Y-mAbs` rare disease drug roundly rejected by FDA AdComm over weakness

Y-mAbs` rare disease drug roundly rejected by FDA AdComm over weakness
Nick Paul Taylor FIERCEBIOTECH
01 Nov 2022
Share Share
Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab

Y-mAbs Announces Outcome of FDA Advisory Committee Meeting on Omburtamab
GLOBENEWSWIRE
29 Oct 2022
Share Share
Y-mAbs Announces Pivotal Data for Omburtamab

Y-mAbs Announces Pivotal Data for Omburtamab
GLOBENEWSWIRE
03 Oct 2022
Share Share
FDA Accepts Y-mAbs` BLA for OMBLASTYS for Neuroblastoma for Priority Review

FDA Accepts Y-mAbs` BLA for OMBLASTYS for Neuroblastoma for Priority Review
GLOBENEWSWIRE
31 May 2022
Share Share
Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA

Y-mAbs Announces Submission of Omburtamab Biologics License Application to FDA
GLOBENEWSWIRE
01 Apr 2022
Share Share
Y-mAbs Provides Regulatory Update on Omburtamab for Neuroblastoma Metastasis

Y-mAbs Provides Regulatory Update on Omburtamab for Neuroblastoma Metastasis
GLOBENEWSWIRE
04 Nov 2021
Share Share
Y-mAbs Takeda Announce Exclusive License and Distribution Agreement

Y-mAbs Takeda Announce Exclusive License and Distribution Agreement
STREETINSIDER
04 Dec 2020
Share Share